gip and glp-1 receptors The possible mechanisms of weight loss caused by GLP-1. GI, GLP-1 Agonist Therapy Center -

They are not intended for human consumption, medical, diagnostic, or therapeutic applications

It predominantly affects women, with over sixty percent of patients reporting a family history of the condition

For example, obese diabetics are a special case and should not be given the full mortality and morbidity benefit for the weight-loss indication in addition to the diabetes indication

Exenatide, semaglutide, and liraglutide are among the medications currently being investigated in clinical studies

LEADER Publication Committee on behalf of the LEADER Trial Investigators

Each medication has other, demonstrated positive health impacts (see the chart below), which can also drive the decision to use one over the other